AI Engines For more Details: Perplexity Kagi Labs You
GABAᴀ Receptor Modulation: Thip hydrochloride selectively activates GABAᴀ receptors, leading to increased inhibitory neurotransmission in the brain. GABAᴀ receptors play a crucial role in regulating neuronal excitability and maintaining the balance between inhibition and excitation in the central nervous system.
Sedative and Hypnotic Effects: Due to its activity at GABAᴀ receptors, thip hydrochloride has sedative and hypnotic properties. It has been investigated for its potential use as a sleep aid or anxiolytic medication. Preclinical studies have shown that thip hydrochloride can induce sedation and promote sleep in animal models.
Anxiolytic Effects: GABAᴀ receptor agonists like thip hydrochloride may also have anxiolytic (anti-anxiety) effects. By enhancing GABAergic neurotransmission, thip hydrochloride may reduce neuronal excitability and dampen anxiety-related behaviors in experimental models.
Potential Therapeutic Applications: While thip hydrochloride has shown promise in preclinical studies, its development as a therapeutic drug has been limited. Some research has explored its potential use in the treatment of sleep disorders, anxiety disorders, and epilepsy. However, further clinical trials would be necessary to evaluate its efficacy and safety in humans for these indications.
Side Effects: Like other drugs that target GABAᴀ receptors, thip hydrochloride may have side effects related to its sedative and hypnotic properties. These may include drowsiness, dizziness, impaired coordination, and cognitive impairment. Additionally, long-term use of GABAᴀ receptor agonists may lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.
Safety Considerations: While thip hydrochloride has been investigated in preclinical studies, its clinical development has been limited, and it is not currently approved for medical use in most countries. More research would be needed to establish its safety and efficacy profile in humans before it could be considered for clinical use.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 0.6 | 0.3 | 1 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.3 | 0.9 | -2 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alzheimer's disease | 0.9 | 1.4 | -0.56 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.3 | 0.9 | -2 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 0.3 | 0.3 | 0 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 1.2 | 0.7 | 0.71 |
| Autism | 0.9 | 1.3 | -0.44 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0 | 0 | |
| Bipolar Disorder | 0.9 | 0.6 | 0.5 |
| Brain Trauma | 0.6 | -0.6 | |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Carcinoma | 0.9 | 0.6 | 0.5 |
| Celiac Disease | 0.3 | 0.9 | -2 |
| Cerebral Palsy | 0.3 | 0.6 | -1 |
| Chronic Fatigue Syndrome | 0.9 | 1.2 | -0.33 |
| Chronic Kidney Disease | 0.3 | 0.7 | -1.33 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.6 | 0.6 | |
| Colorectal Cancer | 0.9 | 0.6 | 0.5 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.6 | 0.7 | -0.17 |
| COVID-19 | 1.1 | 2.2 | -1 |
| Crohn's Disease | 1.2 | 1 | 0.2 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.6 | 0.6 | 0 |
| Depression | 1.2 | 1.4 | -0.17 |
| Eczema | 0 | 0 | |
| Endometriosis | 0.6 | 0.6 | 0 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.8 | 0.8 | |
| Fibromyalgia | 0.5 | 0.4 | 0.25 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.9 | 0 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Gout | 0.6 | 0.6 | 0 |
| Graves' disease | 0.6 | 0.9 | -0.5 |
| Gulf War Syndrome | 0.3 | 0.1 | 2 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.6 | 0.6 | 0 |
| Heart Failure | 0.9 | 0.4 | 1.25 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 1.2 | -1 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.1 | 5 |
| Inflammatory Bowel Disease | 0.9 | 1.7 | -0.89 |
| Insomnia | 0.6 | 0.9 | -0.5 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 0.7 | 0.9 | -0.29 |
| ischemic stroke | 0.6 | 0.6 | 0 |
| Liver Cirrhosis | 1.5 | 1.2 | 0.25 |
| Long COVID | 1.2 | 1.8 | -0.5 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.4 | -0.4 | |
| ME/CFS without IBS | 0 | 0.3 | 0 |
| Metabolic Syndrome | 1.3 | 1.2 | 0.08 |
| Mood Disorders | 1.2 | 1.4 | -0.17 |
| Multiple Sclerosis | 0.6 | 1 | -0.67 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1 | 0.1 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.2 | 0.9 | 0.33 |
| obsessive-compulsive disorder | 0.6 | 0.9 | -0.5 |
| Osteoarthritis | 0.8 | 0.6 | 0.33 |
| Osteoporosis | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 1.2 | 1.8 | -0.5 |
| Polycystic ovary syndrome | 1.2 | 1.2 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 0.3 | 0.7 | -1.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.7 | 1.14 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 1.2 | 0.9 | 0.33 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 0.6 | -0.6 | |
| Sleep Apnea | 0.6 | 0.9 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.6 | -1 |
| Systemic Lupus Erythematosus | 0.9 | 0.3 | 2 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.2 | 0.6 | 1 |
| Type 2 Diabetes | 1.5 | 0.9 | 0.67 |
| Ulcerative colitis | 0.8 | 1.2 | -0.5 |
| Unhealthy Ageing | 0.9 | 0.4 | 1.25 |
| Vitiligo | 0.6 | 0.1 | 5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
